ArticleJournal of cardiac failure2021
Cystatin C and Muscle Mass in Patients With Heart Failure.
Article in Journal of cardiac failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Association of Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate With Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.Kidney medicine · 2026Article
- Acute Kidney Injury in Acute Heart Failure Revisited: Marker of Cardiorenal Disease Severity Rather Than Isolated Renal Injury.Life (Basel, Switzerland) · 2026Review
- Association between sleep duration and sarcopenic obesity: The mediating role of hemoglobin level.PloS one · 2026Article
- Performance of Creatinine and Cystatin C-Based Equations to Estimate Glomerular Filtration Rate Among Patients With Heart Failure.Circulation. Heart failure · 2025Article
- Integrating Novel Biomarkers into Clinical Practice: A Practical Framework for Diagnosis and Management of Cardiorenal Syndrome.Life (Basel, Switzerland) · 2025Review
- The association between cystatin C and hypertension risk in diabetes patients: A multi-cohort cross-sectional study.iScience · 2025Article
- Pre-donation assessment of cystatin C to improve prediction of pre- and post-donation GFR in potential living kidney donors.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- Associations between serum cystatin C and fall reports in an Elderly population.Scientific reports · 2024Article
- Impact of Diabetes Mellitus on Outcomes in Patients with Left Ventricular Assist Devices.Biomedicines · 2024Review
- Serum Cystatin C as a Risk Factor for Supratherapeutic Digoxin Concentration in Elderly Patients with Heart Failure and Chronic Kidney Disease.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Article
- Association of Ratio of eGFR by Cystatin C and Creatinine with Mortality in Heart Failure.Kidney360 · 2024Article
- The potential of cystatin C as a predictive biomarker in pulmonary hypertension.BMC pulmonary medicine · 2023Article
- Hemoglobin level is negatively associated with sarcopenia and its components in Chinese aged 60 and above.Frontiers in public health · 2023Article
- The difference between cystatin C- and creatinine-based assessment of kidney function in acute heart failure.ESC heart failure · 2022Article
- Novel Biomarkers of Kidney Disease in Advanced Heart Failure: Beyond GFR and Proteinuria.Current heart failure reports · 2022Review
- Renal Dysfunction in Patients with Left Ventricular Assist Device.Methodist DeBakey cardiovascular journal · 2022Review
- Left Ventricular Assist Device Implantation and Kidney Function: Chicken, Egg, or Omelet?Kidney medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundThe estimated glomerular filtration rate (eGFR) from cystatin C (eGFRcys) is often considered a more accurate method to assess GFR compared with an eGFR from creatinine (eGFRcr) in the setting of heart failure (HF) and sarcopenia, because cystatin C is hypothesized to be less affected by muscle mass than creatinine. We evaluated (1) the association of muscle mass with cystatin C, (2) the accuracy of eGFRcys, and (3) the association of eGFRcys with mortality given muscle mass. METHODS AND
resultsWe included 293 patients admitted with HF. Muscle mass was estimated with a validated creatinine excretion-based equation. Accuracy of eGFRcys and eGFRcr was compared with measured creatinine clearance. Cystatin C and creatinine were 31.7% and 59.9% higher per 14 kg higher muscle mass at multivariable analysis (both P < .001). At lower muscle mass, eGFRcys and eGFRcr overestimated the measured creatinine clearance. At higher muscle mass, eGFRcys underestimated the measured creatinine clearance, but eGFRcr did not. After adjusting for muscle mass, neither eGFRcys nor eGFRcr were associated with mortality (both P > .19).
conclusionsCystatin C levels were associated with muscle mass in patients with HF, which could potentially decrease the accuracy of eGFRcys. In HF where aberrations in body composition are common, eGFRcys, like eGFRcr, may not provide accurate GFR estimations and results should be interpreted cautiously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.